IQVIA Launches New AI Agents for Life Sciences and Healthcare

June 11, 2025 04:00 AM PDT | By EODHD

Google News:

IQVIA Launches New AI Agents for Life Sciences and Healthcare — Image source: Kalkine Media

Recent News

Kalkine : BSMS Drawing Attention Across Nasdaq Composite Index

Kalkine : Brooge Energy Short Interest Is Rising on Nasdaq Composite

Kalkine : Xylem Performance on NYSE Composite Index Today

Kalkine Captivision Inc Ticker CAPTW Draws Nasdaq Composite Attention

RESEARCH TRIANGLE PARK, N.C., June 11, 2025--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, unveils AI agents at GTC Paris. IQVIA’s new custom-built AI agents using NVIDIA technology are designed to enhance workflows and accelerate insights for life sciences. These live applications of agentic architectures illustrate how IQVIA AI and deep domain expertise are transforming business processes and patient outcomes. "This is a pivotal opportunity to deliver the precise, efficient workflows and insights required by the modern life sciences industry backed by deep industry expertise and powerful technology partnerships," said Bhavik Patel, president of IQVIA Commercial Solutions. "Our collaboration with NVIDIA helps us realize our vision to power smarter healthcare for everyone, everywhere." While IQVIA Healthcare-grade AI® has been delivering insights with the precision, speed and trust required for the life sciences industry across the asset life cycle, this recent collaboration with NVIDIA represents an exciting new phase as we advance the powerful future promised by agentic AI in a way that meets the unique needs of life sciences companies.

Leveraging NVIDIA NIM Agent Blueprints for rapid development, the NeMo Customizer for fine-tuning, and NeMo Guardrails to safeguard deployment, IQVIA is developing agents that help find breakthroughs and simplify operations across life sciences. Use cases for these agentic offerings include target identification, clinical data review, literature review, market assessment, and HCP engagement. "Every moment counts when planning clinical trials, from discovery to commercial application," said Kimberly Powell, vice president of healthcare, NVIDIA. "Working with industry leaders like IQVIA, we can build domain-specific agents that can demonstrate efficiency and precision. One example is Agentic AI helping researchers sift through literature reviews, allowing IQVIA’s thousands of customers the potential to benefit from our collaboration." IQVIA announced a strategic collaboration with NVIDIA in January to build custom foundation models and agentic AI workflows to accelerate research, clinical development and access to new treatments.

AI applications trained on IQVIA’s vast healthcare-specific information will help the industry enhance, streamline, and focus clinical trials and commercial launches with powerful workflow coordination and insights. Story Continues Following NVIDIA GTC Paris, learn more about the future of life sciences at IQVIA TechIQ 2025 in September. The two-day conference held in London will feature insights from industry leaders, including NVIDIA, and is designed to explore strategic approaches to navigate the next frontier of AI. About IQVIA IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise.

IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 88,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. View source version on businesswire.com: https://www.businesswire.com/news/home/20250611916965/en/ Contacts Media Contacts IQVIA: Kerri Joseph, IQVIA Investor Relations ([email protected]) +1.973.541.3558 Alissa Maupin, IQVIA Media Relations ([email protected]) +1.919.923.6785 View Comments

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.